High dose, long-term daily interferon plus ribavirin combination therapy for HCV (genotype 1 and non genotype 1)non responders.

被引：0
|
作者：
Lurie, Y
Beer-Gabel, M
Malnick, SDH
Keter, D
Rimon, E
Mosenkis, B
Stalgis, C
Brass, DD
机构：
[1] Kaplan Hosp, Tel Aviv, Israel
[2] Schering Plough, Bloomfield, NJ USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1837
引用
收藏
页码：620A / 620A
页数：1
相关论文
共 50 条
  • [31] ANALYSIS OF SUSTAINED VIRAL RESPONSE AND BOCEPREVIR RESISTANCE FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV GENOTYPE 1 PRIOR RELAPSERS AND NON-RESPONDERS
    Howe, John A.
    Ogert, Robert A.
    Barnard, Richard J.
    Hazuda, Dada
    Pedicone, Lisa
    Brass, Clifford A.
    Albrecht, Janice K.
    Flamm, Steven L.
    HEPATOLOGY, 2011, 54 : 443A - 443A
  • [32] Gene Polymorphisms of IL-10 and MxA in Responders and Non-responders to Interferon Therapy in HCV Egyptian Patients Genotype 4
    Olfat G. Shaker
    Mohamed T. Abdel-Rahim
    Salma T. Bayoumi
    Cell Biochemistry and Biophysics, 2015, 71 : 617 - 625
  • [33] Gene Polymorphisms of IL-10 and MxA in Responders and Non-responders to Interferon Therapy in HCV Egyptian Patients Genotype 4
    Shaker, Olfat G.
    Abdel-Rahim, Mohamed T.
    Bayoumi, Salma T.
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 71 (02) : 617 - 625
  • [34] Retreatment of high dose IFN (5 mu daily) non-responders with high dose of IFN plus ribavirin.
    Van Thiel, DH
    Friedlander, L
    HEPATOLOGY, 2000, 32 (04) : 353A - 353A
  • [35] STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
    Ferenci, Peter
    Asselah, Tarik
    Foster, Graham R.
    Zeuzem, Stefan
    Sarrazin, Christoph
    Moreno, Christophe
    Ouzan, Denis
    Maevskaya, Marina
    Calinas, Filipe
    Morano, Luis E.
    Crespo, Javier
    Dufour, Jean-Francois
    Bourliere, Marc
    Agarwal, Kosh
    Forton, Daniel
    Schuchmann, Marcus
    Zehnter, Elmar
    Nishiguchi, Shuhei
    Omata, Masao
    Kukolj, George
    Datsenko, Yakov
    Garcia, Miguel
    Scherer, Joseph
    Quinson, Anne-Marie
    Stern, Jerry O.
    JOURNAL OF HEPATOLOGY, 2015, 62 (06) : 1246 - 1255
  • [36] Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy
    Sood, Ajit
    Midha, Vandana
    Goyal, Omesh
    ANNALS OF HEPATOLOGY, 2014, 13 (05) : 503 - 509
  • [37] High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b
    Kanai, K
    Kako, M
    Kumada, T
    Tsubouchi, H
    Aikawa, T
    Kojima, M
    Harada, H
    Kawasaki, T
    Nakashima, M
    Okamoto, H
    Mishiro, S
    ARCHIVES OF VIROLOGY, 1998, 143 (08) : 1545 - 1554
  • [38] High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b
    K. Kanai
    M. Kako
    T. Kumada
    H. Tsubouchi
    T. Aikawa
    M. Kojima
    H. Harada
    T. Kawasaki
    M. Nakashima
    H. Okamoto
    S. Mishiro
    Archives of Virology, 1998, 143 : 1545 - 1554
  • [39] Efficacy of a prolonged αInterferon-ribavirin therapy without or with the addition of amantadine in genotype 1b HCVCAH patients non responders to 6-months retreatment with αInterferon plus ribavirin because of relapse after αInterferon monotherapy.
    Piai, G
    Rocco, P
    Tartaglione, MT
    Ciarleglio, A
    Focareta, R
    Grimaldi, F
    Ievoli, F
    Iuliano, D
    Pacelli, M
    Forte, G
    HEPATOLOGY, 2001, 34 (04) : 581A - 581A
  • [40] A randomized trial of daily vs BID interferon induction followed by combination rebetron therapy for HCV genotype 1 infection.
    Rosen, HR
    Miner, C
    Wolf, SL
    Gretch, DR
    HEPATOLOGY, 1999, 30 (04) : 192A - 192A
12345